Jesús Fuentes Antrás
@JfuentesantrasMedical Oncologist & Clinical Investigator - Experimental Therapeutics Unit, NEXT Oncology - Hospital Universitario Quirónsalud Madrid
Similar User
@AinhoaMada
@lillian_siu
@OlivaM_Onc
@AhernandoCalvo
@DanielAcostaEy1
@ArantzazuBarqu1
@AlfonsoCorts9
@gastonzco
@OncomedHCSC
@ANavarro_MD
@JavierDavidBen2
@ManzanoArancha
@maria_gion
@OlgaMartnezSez1
@AlfredoCarrato
Exciting updates on biomarker discovery, targeting KRAS, FGFR3, MTAPloss, and novel ADCs at #ENASymp24 towards more specific, less toxic therapies for more pts. Many thanks to #EORTC #theNCI #AACR for an insightful meet at the forefront of cancer #drugdevelopment #NEXTOncology
Exciting times to work in oncology. Outstanding #drugdevelop pipelines and innovative diagnostics to bring to patients. Happy to share updates on our @ConquerCancerFd research exploring #breastcancer tumor-informed liquid biopsy and have the oppty to catch up w great colleagues
Lots of food for thought in cancer research at #AACR2024 plus happy to participate in the #GENIE BPC initiative. Updates on our work at UHN using tumor-informed ctDNA to monitor metastatic HR+/HER2- #breastcancer pts on ET+CDK4/6i at poster 25 section 40 @PMResearch_UHN @AACR
Congratulations on this great achievement @lillian_siu @pmcancercentre @UHN
AACR members have elected #AACRFellows Lillian L. Siu, MD, as their 2024-2025 President-Elect. Dr. Siu will become President-Elect on April 8 during the #AACR24 Business Meeting of Members and will assume the Presidency during #AACR25. bit.ly/3TBiQPX
ADC London 2024 kicked off today, exploring advancements in targeted delivery platforms poised to revolutionize tumor treatment. Grateful to contribute sharing insights about combinatorial strategies with ADCs and chemo/targeted therapies @World_ADC #drugdevelopment
If you are interested in #cellcycle science and its impact on innovative #breastcancer therapeutics, check out our recent work seamlessly integrating biological and #drugdevelopment perspectives in Clinical and Translational Medicine onlinelibrary.wiley.com/doi/10.1002/ct…
Thanks to @ConquerCancerFd for this YIA and the continued support of cancer research. Grateful for the inspiring mentorship of #davecescon, @Philippe_Bedard and @lillian_siu in the Phase 1 DDP and BC unit at @pmcancercentre Looking fwd to exploring bespoke ctDNA in advanced BC
Congratulations to three phase I DDP felllows from @pmcancercentre who are 2023 @ASCO @ConquerCancerFd YIA recipients this year - @Esanzgarcia @Jfuentesantras #pavlinaspiliopoulou Well done!
Versionaba el tribunal el art1 de tu cartilla: "La honestidad científica ha de ser la ppal divisa del investigador; debe por consgnte conservarla sin mancha". Orgulloso de mi padre Francisco Fuentes Delgado, desde hoy doctor en Ciencias Sociales y Jurídicas por la @Univcordoba
Medicare to Cover Natera's Signatera MRD Test in Breast Cancer. The payor will reimburse serial monitoring in all subtypes, including HER2-positive and triple negative breast cancers, in patients with stage IIb or higher tumors. ow.ly/xbnE104v4br
Great talks and insight! Thanks to the organizers #bestofSABCS #oncologyeducation
We’re closing out another Best of @SABCSSanAntonio - Canada with @Jfuentesantras discussing what’s in pipeline for novel therapeutics in breast cancer.
JUST OUT @US_FDA 🇺🇸Approves elacestrant in postmenopausal women/adult men w/ER➕HER2➖ESR1🧬mutated advanced or metastatic #BreastCancer w/disease progression following at least 1️⃣line ET Decision based on Efficacy in EMERALD💎 @OncoAlert 🚨@FDAOncology fda.gov/drugs/resource…
New @NatureCancer open access publication: Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. #MBC #bcsm @nlinmd @TariKingMD @DrLisaCarey @RitaNandaMD @claudine_isaacs pubmed.ncbi.nlm.nih.gov/36585450/
🔥Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021 @BioMedCentral doi.org/10.1186/s13045… 👉Comprehensive summary of 120 approvals on oncology @OncoAlert @myESMO
Great start of the Global Oncology Leadership Development Program (GOLD) at @pmcancercentre @PMCancerEdu @UHN Useful framework to shape value-based initiatives against cancer, in great company
Gracias @_SEOM por este premio #SomosFuturo y el increible esfuerzo en #BecasSEOM22 Nadie mejor que @ManzanoArancha para recogerlo. Gran equipo @OncomedHCSC @SomosClinico
Muy orgullosa de recibir en nombre de mi exresi Jesus Fuentes Antrás el premio de #somosfuturo en #SEOM22 Muy merecido 😍
Honored to participate in the Pancreatic Cancer Collective Symposium 2022. Exceptional research and insights @iryxie @BarbaraGrnwald @rudesie_ma Thank you @SU2C @lustgartenfdn @PanCancerCanada @marathonofhope
So much great work from Toronto/PASS-01 team at the Pancreatic Cancer Collective - thank you @PanCancerCanada @SU2C @lustgartenfdn for funding pancreatic cancer research @BarbaraGrnwald @rudesie_ma @Jfuentesantras @graokane @LabNotta
Further framework for ctDNA testing. Reshaping oncology in both early and avanced settings
Just out in Annals of Oncology, the @myESMO recommendations on the use of ctDNA assays 💉🩸 🧬 for patients with cancer: from technical considerations to potential clinical indications including evidence for clinical utility annalsofoncology.org/article/S0923-… @jpascualmd #PrecisionMedicine
Practice changing study: T-DxD significantly improved both PFS & OS in HER2 low MBC. Wonderful news for patients & the field. ADCs changing how we treat breast cancer. Excellent presentation by Dr. Shanu Modi @SocietyofMSKCC @ASCO plenary #bcsm @OncoAlert
Brilliant presentation by @MarlaLipsycMD on ctdna in late HR+ breast cancer! 10% prevalence with 6/8 pts with detectable ctdna having a metastatic recurrence to date #ASCO22 @OncoAlert @DFCI_BreastOnc @hthrparsons
Honored to present our data on advanced PDAC at ASCO. Highly unmet clinical need @ASCO2022 @tfri_research @marathonofhope @pmcancercentre @OICRGenomics
@marathonofhope makes it’s debut at @ASCO #ASCO22 @tfri_research excellent work by @Jfuentesantras et al.
United States Trends
- 1. Bama 27,2 B posts
- 2. Miami 97,5 B posts
- 3. Clemson 14,2 B posts
- 4. South Carolina 22,8 B posts
- 5. XDefiant 8.312 posts
- 6. Cam Payne N/A
- 7. Warde Manuel 1.648 posts
- 8. Ubisoft 7.361 posts
- 9. Africa 261 B posts
- 10. #CFBPlayoff 4.192 posts
- 11. Gundam 96,6 B posts
- 12. #MAFS N/A
- 13. Lindsey 26 B posts
- 14. Eric Dixon N/A
- 15. Cade Phillips N/A
- 16. Hegseth 127 B posts
- 17. Committee 177 B posts
- 18. #tomatoJay 2.457 posts
- 19. #MarriedAtFirstSight N/A
- 20. The CFP 12,1 B posts
Who to follow
-
Ainhoa Madariaga
@AinhoaMada -
Lillian Siu
@lillian_siu -
Marc Oliva
@OlivaM_Onc -
AHernando_Calvo
@AhernandoCalvo -
Daniel Acosta Eyzaguirre
@DanielAcostaEy1 -
Arantzazu Barquin Garcia
@ArantzazuBarqu1 -
Alfonso Cortés Salgado
@AlfonsoCorts9 -
Gastón Zatta
@gastonzco -
OncomedHCSC
@OncomedHCSC -
AlejandroNavarro_MD
@ANavarro_MD -
Javier David Benitez Fuentes
@JavierDavidBen2 -
Arancha Manzano
@ManzanoArancha -
María Gion
@maria_gion -
Olga Martínez-Sáez
@OlgaMartnezSez1 -
Alfredo Carrato
@AlfredoCarrato
Something went wrong.
Something went wrong.